Anavex Life Sciences Q2 2024 GAAP EPS $(0.13) Misses $(0.11) Estimate, Cash and Equivalents of $139.4M
Portfolio Pulse from Benzinga Newsdesk
Anavex Life Sciences (AVXL) reported a Q2 2024 GAAP EPS loss of $(0.13), missing the $(0.11) estimate, marking a 176.47% decrease from the previous year's earnings of $0.17 per share. The company also reported having $139.4M in cash and equivalents.
May 09, 2024 | 11:34 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Anavex Life Sciences reported a significant earnings miss for Q2 2024, with a GAAP EPS loss of $(0.13), missing estimates and showing a substantial decrease from the previous year.
The earnings miss and the significant decrease in earnings compared to the previous year are likely to negatively impact investor sentiment and the stock price of AVXL in the short term. The miss on analyst expectations by 18.18% and the drastic year-over-year decline highlight operational challenges or increased expenses that could concern investors.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100